Bylvay (Odevixibat) Patent Expiration, LOE Window & CMS Spending

Bylvay (Odevixibat) by Ipsen Biopharmaceuticals: FDA Orange Book core substance LOE 2039-06-20 (last listed 2041-11-12), 0 AB generics, $40.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIpsen Biopharmaceuticals
FDA Application & PathwayN215498 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-06-20
Last Listed Patent or Exclusivity Date2041-11-12
Orange Book Patents (*PED Extensions)16 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$40.4M
2024 Medicare Part D Spend$6.4M
2024 Medicaid Spend$34.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel